Editas teases tiny sickle cell sample in effort to climb back into gene editing's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 06, 2022 at 10:42: AM
via Its been a rough and tumble 2022 for Editas Medicine, marked by a new executive team, the suspension of its lead asset and navigating a clinical hold on the efficacy portion of a sickle cell program.

article source
 

<



Similar threads

cafead
Could Editas Medicine Become the Next CRISPR Therapeutics?
Replies
0
Views
115
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Editas and Vertex Ink Deal for Cas9 License for $50M Upfront
Replies
0
Views
75
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH23: Pharma branding, Editas’ high bar and clinical trial diversity
Replies
0
Views
201
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
Replies
0
Views
141
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Editas, in next restructuring step, to sell cell therapy work to Shoreline
Replies
0
Views
270
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote